KKR & Co. Inc. has acquired a majority stake in Healthcare Royalty Management, LLC, with Clarke Futch continuing to lead the company. TD Securities Inc. acted as financial advisor for HCRx. The acquisition was completed on July 30, 2025.
NEW YORK, July 2, 2025—KKR & Co. Inc., a leading global investment firm, has acquired a majority stake in HealthCare Royalty Partners (HCRx), a leading biopharma royalty acquisition company. The acquisition, completed on July 30, 2025, is part of KKR's strategy to expand its capabilities in biopharma royalty and credit investing, as well as its footprint in the life sciences ecosystem [1].
HCRx, founded in 2006 and headquartered in Stamford, Connecticut, has a strong track record of investing in commercial-stage and near-commercial-stage biopharmaceutical assets. Since its inception, the firm has committed over $7 billion in capital and today manages approximately $3 billion in assets, with a portfolio spanning over 10 therapeutic areas and over 55 products [1].
Clarke Futch, HCRx's Chairman and CEO, will continue to lead the company and will maintain an ongoing substantial minority interest in HCRx. The HCRx team will collaborate closely with KKR's health care team to provide a range of financing solutions across the biopharma sector [1].
"This acquisition supports KKR’s ability to provide comprehensive solutions across the health care spectrum and meaningfully expands our life sciences capabilities to address market demand," said Ali Satvat, Partner, Co-Head of Health Care and Global Head of Health Care Strategic Growth at KKR [1].
TD Securities Inc. served as the exclusive financial advisor to HCRx in this transaction [1].
References:
[1] https://finance.yahoo.com/news/kkr-announces-strategic-acquisition-healthcare-130000704.html
[2] https://www.nasdaq.com/articles/kkr-co-acquires-majority-ownership-stake-hcrx
[3] https://www.businesswire.com/news/home/20250730161531/en/KKR-Announces-Strategic-Acquisition-of-HealthCare-Royalty-Partners-Expanding-the-Firms-Health-Care-Franchise-and-Enhancing-its-Life-Sciences-Strategy
Comments
No comments yet